Lilly inks deals to buy 3 vaccine developers for up to $3.8B as M&A spree continues - Fierce Biotech
Earnings
Eli Lilly is acquiring three vaccine developers for up to $3.8B, part of a broader ~$20B M&A spree to build an infectious disease portfolio. The deal signals Lilly is deploying GLP-1 cash flows into pipeline diversification, raising both excitement about strategic optionality and concern about capital allocation discipline.
0 reads·0 theses
Angle
↓ SHORT-5% target+4% stop2-4 weeks tactical
Fade the LLY pop short-term — consensus is already Buy-heavy, insiders are selling, and $20B in M&A spending raises integration risk without near-term EPS catalyst.